Agivera©

Nanozeolite-Based Silver Anti-Microbial

With the proliferation of antibiotic resistant bacteria, and the dramatic fall in the number of antibiotics in development, silver’s antimicrobial role has been known for a long time, and the recent development of nanotechnology along with the synthesis of silver nanoparticles has accelerated their use in the consumer world.

Our silver anti-microbial nanoparticle, Agivera©, is effective against gram positive, gram negative bacteria (including methicillin-and vancomycin resistant bacteria) as well as fungi and viruses. Agivera also acts against bacteria in biofilms, which is a cause of hospital acquired infections (HAI). Our innovation is the use of nanozeolite support, which by chemical modification enhances the antimicrobial properties of the silver via the following:

  • Controlled AgNP size
  • No ligand coating on AgNP
  • Release of co-cation to enhance Ag activity
  • Surface modification of nanozeolite to increase interaction with bacteria
  • Fast and slow release mechanism for silver particles
  • Nanozeolite support from nanometer individual crystals to micron-sized nanoparticle aggregates

Our antimicrobial product with significantly higher potency requires lower dosages of silver with a lower environmental footprint and lower non-bacterial cellular interactions.  Most current supports for silver, such as polymers, textiles, chitosan, metals do not add significant synergistic value to the activity of the silver.  Use of the unique features of the nanozeolite to enhance the silver antimicrobial activity is the transformational aspect of our product.

Product Information

Product Type: Powder or Dispersion
Product Name: Agivera© F [Fast release silver]
Agivera© S [Slow release silver]
Particle Size: 30 nm to micron-size aggregates

Performance of Agivera©

Test Results for Agivera F (FRAg: fast release silver) and Agivera S (SRAg: slow release silver)
Controls
7 to 8 log 10 reduction of bacteria counts (CFU/ml)
Testing Notes:
  • Substrate : 30-40 nm transparent, dispersible NZ crystals (agglomerate size controlled from nanometers to microns)
  • Conditions for antimicrobial testing: E.coli, FRAg, SRAg = 100 µg/ml, 37 °C, 75 min
  • MIC (MBC) of FRAg 1.56 micrograms/ml; SRAg 3.125 micrograms/ml (positive control ampicillin 0.5 micrograms/ml) towards E.coli (2.5x104 CFU/ml)